BillionToOne Revolutionizes Prenatal Care with Dual Launch of Innovative NIPTs BillionToOne introduces two groundbreaking non-invasive prenatal tests, enhancing fetal antigen screening for a safer pregnancy experience. Learn more!

BillionToOne Revolutionizes Prenatal Care with Dual Launch of Innovative NIPTs #USA #Menlo_Park #Prenatal_Testing #BillionToOne #Fetal_Antigens

BillionToOne Introduces Northstar Select® for Advanced Lung Cancer Study in Japan BillionToOne announces the inclusion of Northstar Select® as a liquid biopsy test in a major lung cancer study in Japan, enhancing patient treatment options.

BillionToOne Introduces Northstar Select® for Advanced Lung Cancer Study in Japan #Japan #Lung_Cancer #BillionToOne #Kashiwa #Northstar_Select

BillionToOne Welcomes Anthony Pagano as New Audit Committee Chair and Board Member BillionToOne, a leader in molecular diagnostics, appoints Anthony Pagano to its Board of Directors, reinforcing its commitment to innovation and growth.

BillionToOne Welcomes Anthony Pagano as New Audit Committee Chair and Board Member #United_States #Menlo_Park #BillionToOne #Genmab #Anthony_Pagano

Türk dehasından tarihi başarı! Milyarlarca dolarlık dev oldu ABD'de Stanford Üniversitesi'nde sistem biyolojisi alanında doktora yapan Türk girişimci Oğuzhan Atay'ın 2016 yılında kurduğu Menlo Park merkezli BillionToOne şirketi, Nasdaq borsasında halka açılarak 273 milyon dolar topladı. Atay, şirketi orak hücreli anemi ve kistik fibroz gibi yaygın hastalıklar için noninvaziv (kan örneğiyle yapılan) genetik testler geliştirme hedefiyle kurmuştu. HİSSELERİ İLK GÜNDEN DEĞER KAZANDI Borsadaki ilk işlem gününün sonunda şirketin hisseleri yüzde 80 artarak 109 dolara çıktı ve şirketin piyasa değeri 5,8 milyar dolara ulaştı. Bu değerleme ile Atay’ın şirketteki payının değeri 335 milyon dolara, kurucu ortağı ve Teknolojiden Sorumlu Başkanı (CTO) David Tsao’nun payıysa yaklaşık 325 milyon dolara yükseldi. Forbes’a açıklamalarda bulunan Oğuzhan Atay, "Her projeksiyonumuzu aştık. Piyasayı değiştirmeye değil, teknolojik riski üstlenip gerçekten fark oluşturmaya odaklanıyoruz" ifadelerini kullandı. DOĞUM ÖNCESİ TESTTEN KANSER TEŞHİSİNE Şirketin adını aldığı patentli teknoloji, 3 milyar DNA bazından yalnızca tek bir harf değişikliğini bile tespit edebiliyor. Bu sayede sadece bir kan örneğiyle, bir bebeğin genetik hastalık taşıma riski belirlenebiliyor. Başlangıçta doğum öncesi testlerle yola çıkan şirket, 2023 yılında kanser tanısına yönelik testleri de portföyüne ekledi. Şirket, şimdi de tıp dünyasında "değerli kase" olarak görülen kanserin erken tespiti için yeni testler geliştiriyor. BillionToOne, 30 Haziran 2025 itibarıyla son 12 ayda 508 bin genetik testten 209 milyon dolar gelir elde etti. Bu rakam, şirketin 2021'deki 8 milyon dolarlık gelirine kıyasla 19 katlık bir artışa işaret ediyor. Şirket henüz kâra geçmemiş olsa da, zararı 2025'in ilk yarısında 4 milyon dolara kadar geriledi. Kaynak: HABER7.COM#ESHAHABER.COM.TR #haber #gündem #sondakika #news #press #worldnews

Güncel News press Türk dehasından tarihi başarı! Milyarlarca dolarlık dev oldu #TürkGirişimci #BillionToOne #OğuzhanAtay #GenetikTest #Stanford

Funding Raises: #Metropolis $500M Series D; #Ripple $500M Strategic; #Armis $435M pre-IPO Funding; #BillionToOne $273.1M IPO; #BeaconSoftware $250M Series B; #Synchron $200M Series D; #BraveheartBio $185M Series A; #Evommune $150M IPO; : #HippocraticAI $126M Series C

Gunderson Dettmer Successfully Navigates BillionToOne's $273.1 Million IPO Amidst Market Complexities Gunderson Dettmer represented BillionToOne in a successful IPO, raising $273.1 million. Discover how they overcame market challenges.

Gunderson Dettmer Successfully Navigates BillionToOne's $273.1 Million IPO Amidst Market Complexities #United_States #Redwood_City #IPO #BillionToOne #Gunderson_Dettmer

New Insights Highlight Burdens of Monitoring Alloimmunized Pregnancies With Antigen-Negative Fetuses A recent study reveals the unnecessary monitoring burden in alloimmunized pregnancies with antigen-negative fetuses, proposing a more efficient testing method.

New Insights Highlight Burdens of Monitoring Alloimmunized Pregnancies With Antigen-Negative Fetuses #United_States #Menlo_Park #HDFN #BillionToOne #cfDNA_testing

BillionToOne's Innovative Cystic Fibrosis Screening Enhances Treatment Choices for Expecting Parents BillionToOne's UNITY Screen revolutionizes cystic fibrosis prenatal testing, providing 100% sensitivity and a wider range of treatment options for parents-to-be.

BillionToOne's Innovative Cystic Fibrosis Screening Enhances Treatment Choices for Expecting Parents #USA #Menlo_Park,_California #cystic_fibrosis #BillionToOne #UNITY_Screen

BillionToOne Unveils Northstar Select® with Exceptional Sensitivity in Oncology Testing BillionToOne's Northstar Select® has shown superior sensitivity in genomic profiling when tested against existing assays, providing better insights for cancer treatment.

BillionToOne Unveils Northstar Select® with Exceptional Sensitivity in Oncology Testing #United_States #Liquid_Biopsy #Menlo_Park #BillionToOne #Northstar_Select

BillionToOne Welcomes New Executives to Transform UNITY and Northstar Platforms BillionToOne, a molecular diagnostics firm, announces leadership additions to enhance UNITY and Northstar platforms, driving growth and innovation.

BillionToOne Welcomes New Executives to Transform UNITY and Northstar Platforms #United_States #Menlo_Park #BillionToOne #Northstar_Select #UNITY_Complete

BillionToOne Introduces Enhanced UNITY Fetal Risk Screen for Prenatal Testing BillionToOne has launched an upgraded version of the UNITY Fetal Risk™ Screen, enabling early assessment of numerous genetic conditions from a single blood sample.

BillionToOne Introduces Enhanced UNITY Fetal Risk Screen for Prenatal Testing #United_States #Menlo_Park,_California #Prenatal_Testing #BillionToOne #UNITY_Fetal_Risk

BillionToOne Welcomes Dr. Haywood Brown as New Chief Medical Officer for Prenatal Services BillionToOne has appointed Dr. Haywood Brown as their new Chief Medical Officer for Prenatal. With over three decades of experience, he aims to enhance maternal and fetal health.

BillionToOne Welcomes Dr. Haywood Brown as New Chief Medical Officer for Prenatal Services #USA #Menlo_Park #BillionToOne #Dr._Haywood_Brown #prenatal_care

BillionToOne Unveils Groundbreaking Findings at Upcoming AACR 2025 Meeting BillionToOne is set to showcase its cutting-edge liquid biopsy technologies at the AACR Annual Meeting 2025, promising advances in cancer diagnostics.

BillionToOne Unveils Groundbreaking Findings at Upcoming AACR 2025 Meeting #United_States #Chicago #Liquid_Biopsy #BillionToOne #AACR

BillionToOne Achieves Major Milestone with One Million UNITY Prenatal Tests BillionToOne celebrates a significant achievement by surpassing one million UNITY prenatal tests, revolutionizing prenatal care with its non-invasive technology.

BillionToOne Achieves Major Milestone with One Million UNITY Prenatal Tests #USA #Menlo_Park #Unity #Prenatal_Testing #BillionToOne

BillionToOne’s Northstar Response® Sets New Standards in Cancer Treatment Monitoring BillionToOne reveals its Northstar Response® test, validated by a peer-reviewed study, enhancing the monitoring of cancer therapy responses with unprecedented precision.

BillionToOne’s Northstar Response® Sets New Standards in Cancer Treatment Monitoring #United_States #Menlo_Park #Precision_Diagnostics #BillionToOne #Nordstar_Response

BillionToOne Achieves Major Milestone with 100% Accuracy in Non-Invasive Fetal RhD Detection Study BillionToOne has announced groundbreaking results from a US study showcasing 100% accuracy in non-invasive fetal RhD detection, revolutionizing prenatal care.

BillionToOne Achieves Major Milestone with 100% Accuracy in Non-Invasive Fetal RhD Detection Study #United_States #Menlo_Park #Prenatal_Testing #BillionToOne #RhD_Detection

BillionToOne Achieves Impressive Revenue Growth Over 100% in 2024 BillionToOne, a leader in molecular diagnostics, reported over 100% revenue growth in 2024, driven by advancements in prenatal testing and oncology markets.

BillionToOne Achieves Impressive Revenue Growth Over 100% in 2024 #United_States #Menlo_Park #Prenatal_Testing #BillionToOne #Oncology_Liquid_Biopsy

BillionToOne to Showcase Innovations at 43rd J.P. Morgan Healthcare Conference BillionToOne is set to present at the prestigious 43rd Annual J.P. Morgan Healthcare Conference, showcasing their work in molecular diagnostics.

BillionToOne to Showcase Innovations at 43rd J.P. Morgan Healthcare Conference #United_States #San_Francisco #Conference #diagnostics #BillionToOne

BillionToOne's UNITY Test Revolutionizes Maternal Healthcare in Remote Areas BillionToOne is transforming maternity care with its UNITY non-invasive prenatal test, improving access for pregnant women in remote areas and reducing travel burdens.

BillionToOne's UNITY Test Revolutionizes Maternal Healthcare in Remote Areas #United_States #Menlo_Park #Maternal_Care #BillionToOne #UNITY_Test